Clinical Trials Update: June 28, 2006
Keratoses Metastatic Melanoma Parkinson's Disease
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This study will evaluate the safety and efficacy of an investigational medication to treat Actinic Keratosis (AK). Participants must be at least 18 years of age with five or more clinically recognizable Actinic Keratosis (palpable and/or visible to unaided eye) on the face, ears, or scalp. The study will require six clinic visits over eight weeks.
The research site is in West Palm Beach, Fla.
OncoVEXGM-CSF is being evaluated to treat malignant melanoma that can no longer be treated by surgery. Volunteers 18 or older who have stage IIIc or stage IV melanoma that is inoperable and who have one or more tumors that are accessible for direct injection may qualify. Participants must not have a history of other malignancies within the prior five years.
The research sites are located throughout the United States.
This study will evaluate whether a combination of carbidopa/levodopa/entacapone provides greater benefit than the combination of carbidopa/levodopa in treating symptoms of early Parkinson's disease. Candidates may be included who are 30-80 at the time of Parkinson's diagnosis, and have at least two cardinal signs of disease: resting tremor, bradykinesia, or rigidity. People with a diagnosis of Parkinson's for more than five years are not eligible.
The research site is in Southfield, Mich.
Copyright 2006 Thomson CenterWatch. All rights reserved.